Small Cap Feast
Small Cap Feast – 30 July 2019
Dish of the Day:
No Joiners Today
No Joiners Today
Off the Menu:
No Leavers Today
No Leavers Today
What’s Cooking in the IPO Kitchen?
Freyherr International Group PLC the Medicinal Cannabis holding company established in 2016, is planning to list on the NEX exchange on the 13 August
Beximco Pharma (BXP.L) 42.00p £168.31m
Beximco Pharmaceuticals, a drug manufacturer primarily in emerging markets providing access to affordable medicine, has launched its fifth product to the US market. The drug Nadolol aims to treat blood pressure and angina pectoris (chest pain). The total market for Nadolol in the US stood at more than $63m in 2018 according to IQVIA audited research. Nadolol is available in 20, 40 or 80 mg doses and is taken 0rally (by mouth).
The launch follows the successful release and export of Carvedilol, Sotalol, Methocarbamol and Metformin to the US markets. The release is consistent with Beximco’s earlier moves following the approval of its manufacturing site in the US by the FDA. Expected to be launched by the company’s US distribution partner, Bayshore Pharmaceuticals LLC, the product is a generic equivalent of Bristol-Myers Squibb’s Corgard.
Beximco is the only Bangladeshi company to export pharmaceutical products to the US, which according to Managing Director Nazmul Hassan is “a validation” of Beximco’s “expertise in offering specialised generic products in a global setting. “
MC Mining (MCM.L) 41.50p £58.47m
The emerging developer and producer of high-quality coking and thermal coal, today announced its results for the quarter ended 30 June 2019. Its production, sales and revenue for the final quarter of its financial year declined due to pressure on coal prices. In dollar terms, the price per tonne was down 27% over the quarter, at USD70.87 (17% lower in South African rand terms). Production costs also rose by 1.9% to USD 48.90 from USD 48.00 the year before. Production dropped 11% to 121,742 tonnes from the same period in the financial year before.
Although many key metrics declined the company maintained the period was successful, with a notable update being the conclusion of a hard coking coal off-take agreement with ArcelorMittal South Africa Ltd for yearly purchases of 350,000 to 400,000 tonnes that will be produced at the Makhado coking coal project in South Africa.
MC has been approved by the Industrial Development Corp of South Africa Ltd for a ZAR245m term loan facility, which will form part of the funding package for phase one of the aforementioned Makhado project.
AP14 thermal coal prices remained under pressure, with the average price dropping from USD67/tonne from USD100 the previous year, due to competition from higher liquefied natural gas supply and low demand in some parts of the northern hemisphere.
Kape Technologies (KAPE.L) 82.00p £118.04m
KAPE Technologies, a security as a service (SaaS) company focused on helping consumers globally have a greater experience with digital protection, provided a trading update for the six months ended 30 June 2019. The company continued to trade strongly through the first half, underpinned by Kape’s consumer acquisition strategy and also some new product initiatives. H2 2019 revenue is expected to be c.$29.6m, up from $24.1m the previous year. This was driven by “growth in sales of Kape’s suite of digital privacy products”. Adjusted EBITDA is expected to be c. $5.8m, up 40.2% from H1 2018.
R&D remains a key focus, to achieve the end goal of supporting their customers’ widening digital privacy requirements. The end-market for Kape is experiencing strong growth, due to the new ZenMate solutions introduced in the period. Two new macOS malware security threats were also exposed through the group’s endpoint security solution, which Kape users are now fully protected against. The Group expects to report its interim results for the six months ended 30 June 2019 on the 17 September 2019.
Transense Technologies (TRT.L) 63.00p £9.87m
Transense Technologies plc, the provider of sensor systems for the industrial, mining and transportation markets, provided a trading update for the year ended 30 June 2019.
Over the second half of the year, revenues improved continuously, so full year revenues were ahead of the board’s previous expectations at c. £2.20m, from £2.05m in the 2018 financial year. A notable highlight was that subscription income arising from large mining haul trucks using Translogik’s iTrack II tyre monitoring system grew considerably reaching approximately £0.98m for the full year (FY18: £0.61m).
In February 2019 Transense announced an initial order with a major supplier to the mining marketplace. Transense believe that this activity offers potential for substantial future growth. However, revenue from Translogik probes reduced from record levels in the previous financial year, partly due to reduced promotional activity because of spend control before the Company’s placing announced in March 2019.
CEO Graham Storey commented that although revenues from Probe and SAWSense fell during the period, the level of activity was still encouraging, and Transense will in due course provide a further update with its final results.
NWF Group (NWF) 167.00p £80.93m
NWF Group, a specialist agricultural and distribution business delivering feed, food and fuel across the UK, announced its final results for the year ended 31 May 2019. Revenue was up 9.9% to £671.3m from 2018, however headline operating profit was down 3.8% over the same period to £10.2m. This led to headline profit before taxation dropping 4.9%, and headline EPS dropping 5.4%.
The results were ahead of original market expectations but behind the prior year (which was a record for the company). All three divisions saw revenue growth, which was a result of increased activity and higher commodity prices. Notably, there was strong profit improvement in its Food division, from improved operational effectiveness with new customers. In Fuels, despite a mild winter, performance was good and volumes were added to by 20%. For feeds, results were stable as strong summer demand was offset by weaker winter demand.
Although net debt rose £4m to £10.4m, the company’s balance sheet remains strong with net debt at 0.7x EBITDA. The Board’s confidence in the business has shown from the increase in dividend per share from 6.3 p to 6.6p.
Advanced Medical Solutions Group (AMS) 290.00p £618.44m
Advanced Medical Solutions Group plc, the surgical and advanced wound care specialist company, announced that it has received 510(k) approvals from the US FDA (“Food and Drug Administration”) for its Silver High Performance Dressing and Silicone PHMB Foam Dressing. Both products will be commercialised via AMS’s network of woundcare partners and distributors in FDA approved markets.
Silver High Performance Dressing is a next generation antimicrobial gelling fibre technology with patent protected construction. It delivers sustained antimicrobial activity for up to seven days and the dressing is used for chronic wounds such as ulcers, diabetic foot ulcers, post-operative surgical wounds, and graft and donor sites.
Silicone PHMB adds to AMS’s existing PHMB Foam Range and gives AMS and its commercial partners increased access to the antimicrobial foam market in the US, worth more than $100m and growing at 6% year on year. AMS has begun the process to gain CE mark approval in Europe for Silicone PHMB which the company expects to complete in the first half of the 2020 financial year.
Keras Resources (KRS) 0.47p £10.87m
Keras Resources, a technology metals development company, provided an update on Calidus Resources, which it holds an approximately 35.8% stake in. Calidus’ update was as follows:
Excellent drill results, including intercepts of up to 1m @ 107.16g/t Au from 36m, were returned from recent infill drilling inside and adjacent to the Klondyke Prospect (‘Klondyke’), underpinning a potential resource upgrade. Emphasis has now been placed on upgrading the category of the resource to allow additional resources to be declared.
An additional benefit is that the results will now provide detailed knowledge of the orebody for accurate grade modelling. A 12,000m drilling program is now underway with this in mind. Calidus is continuing work towards extending the life of the mine, while also further de-risking the mine through project enhancements. These all serve to improve the commercial viability of the Warrawoona project.
Once the Primary Feasibility Study (PFS) of the Warrawoona Project is completed, Keras will be issued an additional 265m Performance Shares in Calidus.
European Lithium (NEX:EUR) 7.3p £43.1m
European Lithium Limited, a mining exploration and development company focusing on its wholly owned Wolfsberg Lithium Project in Austria, announced its quarterly report for the three months ending 30 June 2019.
Key updates are as follows:
Darfner/Anzaplan has commissioned the pilot plant and conducts metallurgical test work and pilot processing.
Its summer drilling program is ongoing with drill rigs operating onsite to convert JORC resource inferred into Measured and Indicated category and upgrade resources to 10.98mt.
The Company announced that it would be undertaking a placement, mainly to European based sophisticated investors, at an issue price of $0.09 per share to raise proceeds of up to EUR1.5million (before expenses).
During this quarter the Company issued 18.2m shares, raising cash proceeds of $1,638,000 before expenses.
Fastjet (FJET) 1.48p £56.06m
Fastjet, an African value airline, has announced its unaudited Interim Results for the six months to 30 June 2019, together with its strategic and operational developments.
Revenue was up to $19,731,000 from $14,479,000 in the corresponding period for the last financial year. This contributed to a decrease in the loss for the period after tax to around $10,110,000.
Cash balance at the end of the period for the company was up slightly to $3,415,000 from $3,312,000.
Physiomics* (PYC) 3.35p £2.44m
Physiomics plc, a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, confirmed that based on its unaudited management accounts for the year ended 30 June 2019, the Company is trading in line with analyst expectations.
Physiomics expects to publish its final audited results for the year ending 30 June 2019 during the week commencing 30 September 2019.
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email email@example.com with “unsubscribe me”.